Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Sep 20;36(5):2489–2500. doi: 10.3892/or.2016.5112

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Stratification analysis for prognostic performance of SHMT2 in subgroups of ER-negative and ER-positive breast cancers. For the public breast cancer microarray data, we pooled all eligible breast cancers after normalization. (A) Cox proportional hazard analysis of SHMT2 for OS in ER-negative and ER-positive breast cancer. (B) Comparison of prognostic value of SHMT2 for PFS between ER-negative and ER-positive breast cancer. (C) Kaplan-Meier analysis was used to visualize the dose-dependent relationship between SHMT2 and the OS in ER-negative breast cancer. (D) mRNA levels of SHMT2 and OS in ER-positive breast cancer. (E) Comparing the prognostic performance of SHMT2 with other factors in ER-negative breast cancers. The HR of OS for various expression levels of SHMT2, HER2, lymph node involvement, distant metastasis, Elson grade, uPA and RRM2 were determined using Cox proportional hazard analysis. LN, lymph node; Met, metastasis; ^*p<0.05, ^**p<0.01.